Brazil's National Health Surveillance Agency (ANVISA) approved a new indication for the Gardasil 9 vaccine on February 16, 2026, between 5:15 PM and 8:15 PM UTC, extending protection to oropharyngeal, head, and neck cancers for individuals aged 9 to 45 years, including children, men, and women. The decision was announced by ANVISA's official Twitter account (@anvisa_oficial), as reported by CanalGov. The approval boosts HPV immunization efforts in Brazil, according to the CanalGov post citing ANVISA. Gardasil 9, previously indicated for other HPV-related conditions, now covers these additional cancer types across the specified age group. This development occurred within the three-hour reporting window ending at 8:15 PM UTC on February 16, 2026, with no prior related reports noted.
